Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.

Chengqian Yin,Bo Zhu,Ting Zhang,Tongzheng Liu,Shuyang Chen,Yu Liu,Xin Li,Xiao Miao,Shanshan Li,Xia Mi,Jie Zhang,Li,Guo Wei,Zhi-xiang Xu,Xiumei Gao,Canhua Huang,Zhi Wei,Colin R. Goding,Peng Wang,Xianming Deng,Rutao Cui

DOI: https://doi.org/10.1016/j.cell.2019.01.002

IF: 64.5

2019-01-01

Cell

Abstract:Activating mutations in NRAS account for 20%-30% of melanoma, but despite decades of research and in contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here, we identify a previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates NRAS to enhance its binding to its downstream effectors and promotes oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N substitution in STK19 whose alterations were identified in 25% of human melanomas represents a gain-of-function mutation that interacts better with NRAS to enhance melanocyte transformation. STK19(D89N) knockin leads to skin hyperpigmentation and promotes NRAS(Q61R)-driven melanomagenesis in vivo. Finally, we developed ZT-12-037-01 (1a) as a specific STK19-targeted inhibitor and showed that it effectively blocks oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo. Together, our findings provide a new and viable therapeutic strategy for melanomas harboring NRAS mutations.